• Home
• Research and projects
• Our research summaries
• Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)